文献速递慢性肾脏病

慢性肾脏病中的铁缺乏:病理生理学、诊断与治疗更新

Iron Deficiency in Chronic Kidney Disease: Updates on Pathophysiology, Diagnosis, and Treatment.
PubMed 文献 · J Am Soc Nephrol · 2020-02-10

本文综述慢性肾脏病(CKD)中铁缺乏的病理生理、诊断与治疗。铁缺乏(绝对或功能性)是CKD贫血的重要机制,传统生物标志物诊断有局限。文章讨论口服与静脉铁剂治疗证据及更宽松补铁策略和静脉对比口服铁剂的风险获益。

要点

  • CKD贫血中铁缺乏可为绝对性或功能性,均影响红细胞生成。
  • 传统铁缺乏诊断标志物在CKD患者中有局限性,检测与监测仍具挑战。
  • 需权衡更宽松补铁策略及静脉与口服铁剂的风险和获益。

核心结论

  • 铁缺乏在CKD贫血中起重要作用,可为绝对性或功能性铁缺乏。
  • 传统诊断标志物在CKD患者中有限,铁缺乏性贫血检测与监测仍具挑战。
  • 治疗需权衡更宽松补铁策略及静脉与口服铁剂的风险和获益。

研究设计与样本

  • 综述,检索范围未在摘要中报告。

主要发现

  • CKD中绝对和功能性铁缺乏的风险因素包括失血、铁吸收受损和慢性炎症。
  • 相对促红细胞生成素生成不足是CKD贫血主要驱动因素,铁缺乏是加重红细胞生成受损的突出机制。

临床怎么用

  • 综述讨论现有指南所依据的文献及口服与静脉铁剂制剂,供CKD铁缺乏性贫血治疗参考。

局限性

  • 传统铁缺乏诊断标志物在CKD患者中有局限性,导致检测和监测持续存在挑战。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Anemia is a complication that affects a majority of individuals with advanced CKD. Although relative deficiency of erythropoietin production is the major driver of anemia in CKD, iron deficiency stands out among the mechanisms contributing to the impaired erythropoiesis in the setting of reduced kidney function. Iron deficiency plays a significant role in anemia in CKD. This may be due to a true paucity of iron stores (absolute iron deficiency) or a relative (functional) deficiency which prevents the use of available iron stores. Several risk factors contribute to absolute and functional iron deficiency in CKD, including blood losses, impaired iron absorption, and chronic inflammation. The traditional biomarkers used for the diagnosis of iron-deficiency anemia (IDA) in patients with CKD have limitations, leading to persistent challenges in the detection and monitoring of IDA in these patients. Here, we review the pathophysiology and available diagnostic tests for IDA in CKD, we discuss the literature that has informed the current practice guidelines for the treatment of IDA in CKD, and we summarize the available oral and intravenous (IV) iron formulations for the treatment of IDA in CKD. Two important issues are addressed, including the potential risks of a more liberal approach to iron supplementation as well as the potential risks and benefits of IV versus oral iron supplementation in patients with CKD.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Batchelor EK, Kapitsinou P, Pergola PE, et al. Iron Deficiency in Chronic Kidney Disease: Updates on Pathophysiology, Diagnosis, and Treatment. J Am Soc Nephrol. 2020. PMID: 32041774. doi:10.1681/ASN.2019020213

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。